Tirzepatide
- Generic Name
- Tirzepatide
- Brand Names
- Mounjaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2023788-19-2
- Unique Ingredient Identifier
- OYN3CCI6QE
- Background
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclini...
- Indication
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 108
- Registration Number
- NCT06073184
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 400
- Registration Number
- NCT06047548
- Locations
- 🇺🇸
New Horizon Research Center, Miami, Florida, United States
🇺🇸Alliance for Multispecialty Research, LLC, Norman, Oklahoma, United States
🇺🇸Pinnacle Clinical Research, San Antonio, Texas, United States
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 350
- Registration Number
- NCT06037252
- Locations
- 🇺🇸
Care Access - Aurora, Aurora, Colorado, United States
🇺🇸Chase Medical Research, LLC, Waterbury, Connecticut, United States
🇺🇸Medical Advancement Centers of Arizona, Tempe, Arizona, United States
Effect of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 32
- Registration Number
- NCT06009653
- Locations
- 🇺🇸
Sansum Diabetes Research Institute, Santa Barbara, California, United States
A Study of Tirzepatide (LY3298176) in Healthy Lactating Females
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 11
- Registration Number
- NCT05978713
- Locations
- 🇺🇸
Las Vegas Clinical Research Unit - PPD, Las Vegas, Nevada, United States
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 168
- Registration Number
- NCT05963022
- Locations
- 🇨🇳
Dalian University - The Affiliated Zhongshan Hospital, Dalian, Liaoning, China
🇨🇳Pudong New Area People's Hospital Shanghai, Shanghai, Shanghai, China
🇨🇳Jiangxi Pingxiang People's Hospital, Pingxiang, Jiangxi, China
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 66
- Registration Number
- NCT05912621
- Locations
- 🇺🇸
Clinical and Translational Research Unit, Palo Alto, California, United States
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 751
- Registration Number
- NCT05822830
- Locations
- 🇺🇸
Southern California Dermatology, Inc., Santa Ana, California, United States
🇺🇸University Clinical Investigators, Inc., Tustin, California, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices
- Conditions
- Interventions
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 65
- Registration Number
- NCT05810597
- Locations
- 🇺🇸
ICON, Salt Lake City, Utah, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸ICON Early Phase Services, San Antonio, Texas, United States
Role Of Metabolic Adaptation In Weight Regain
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Pennington Biomedical Research Center
- Target Recruit Count
- 27
- Registration Number
- NCT05766358
- Locations
- 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.